Fennec Pharmaceuticals Inc.: financial analysis
Ratios worked out from 10 fiscal years of Fennec Pharmaceuticals Inc.'s statements, compared with 675 companies in Biotechnology.
Fennec Pharmaceuticals Inc. scorecard#
Passes 8 of the 20 checks that could be worked out: strongest in growth (3 of 5), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 31, 2026.
Valuation1 of 5
- ✗P/E below its peers' median185.1×P/E 185.1× against Biotechnology's median of 17.5×.
- ✗Price to book below its peers' median10.5×Price to book 10.5× against Biotechnology's median of 2.8×.
- ✓Price to sales below its peers' median5.6×Price to sales 5.6× against Biotechnology's median of 8.4×.
- ✗Free cash flow yield above 5%-0.6%Free cash flow is -0.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yield0.5%Earnings yield 0.5% against the 10-year Treasury's 4.92% on 2026-11-20.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 5
- ✗Revenue grew in the newest year-6.1%Revenue down 6.1% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years207.2%207.2% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median207.2%207.2% a year against Biotechnology's median of 12.9% (184 companies).
- ✗Earnings per share grew in the newest year-0.34 vs -0.02Diluted EPS -0.34 in fiscal 2025 against -0.02 the year before (report's currency).
- ✓Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$18 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 5
- ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-14.1%-14.1% against Biotechnology's median of -60.5% (246 companies).
- ✗Return on equity above 15%-65.8%-65.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-14.1%-14.1% in fiscal 2025 against -1466.9% in 2022.
Financial health2 of 4
- ✓Short-term assets cover short-term liabilities6.4×Current ratio 6.37 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-3.0×Operating income -3.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone3.14Z-score 3.14 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.7%Diluted shares up 4.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Revenue fell 6.1% against the year before.
- Net loss of $10 million, the 12th loss-making year in a row.
- Operating income covers the interest bill only -3.0 times.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profitno
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuedno
- Gross margin rosenot on file
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.80 | × 1.2 | 0.96 |
| Retained earnings to assets | -3.25 | × 1.4 | -4.55 |
| Operating income to assets | -0.09 | × 3.3 | -0.29 |
| Market value to liabilities | 10.66 | × 0.6 | 6.39 |
| Revenue to assets | 0.63 | × 1 | 0.63 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 94.1% | 94.2% | — | 74.8% | — | |
| Operating margin | -14.1% | 5.4% | -60.1% | — | — | -60.5% | 64% | |
| Net margin | -21.8% | -0.9% | -75.5% | — | — | -70.4% | 62% | |
| Return on equity | -65.8% | — | — | — | -77.4% | -61.5% | 46% | |
| Return on assets | -16.9% | -1.2% | -59.6% | -96.1% | -64.5% | -44.8% | 78% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -6.1% | 123.7% | — | — | — | 16.0% | 26% | |
| Revenue growth, 3 years a year | 207.2% | — | — | — | — | 12.9% | 99% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | — | — | — | — | 0.32× | 0.26× | — | |
| Net debt | — | $-7 M | $18 M | $1 M | $-16 M | $-16 M | — | |
| Interest cover | -3.02× | 0.63× | -3.77× | — | — | -22.16× | 84% | |
| Current ratio | 6.37× | 6.38× | 3.56× | 5.80× | 13.57× | 4.55× | 62% | |
| Equity share of assets | 50.3% | -13.1% | -43.3% | -9.5% | 70.4% | 64.2% | 38% |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.77× | 1.32× | 0.79× | 0.06× | — | 0.26× | 87% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).